Use of albumin in intensive care unit patients--is continuous quality assessment necessary?
BACKGROUND
There are two main reasons for hypo-albuminaemia in severely ill patients: long-lasting malnutrition and metabolic response to stress. Hypo-albuminaemia is therefore a prognostic indicator of illness severity rather than a cause of disease. Supplementation with albumin has not yet been demonstrated to have measurable therapeutic effects. Hypovolaemia is often seen in intensive care unit (ICU) patients, either postoperatively or caused through shock. The main goal of any treatment is to maintain adequate intravascular filling. No clear benefit can be seen when using albumin instead of artificial colloids.


OBJECTIVE
Based on the literature, we performed an intervention study to evaluate and improve the use of albumin.


METHODS
After evaluation of the use of albumin over the last 4 years (by means of analysis of the pharmacy drug use statistics), all staff members of the ICU were invited to discuss information retrieved from recently published literature. This led to the introduction of the following new guidelines. Albumin may only be given to patients with very low serum albumin levels of less than 15 g/litre. Substitution of albumin between levels of 15-20 g/litre may take place if patients are in poor condition. The indication has to be documented in the patient's notes.


RESULTS
After the introduction of the guidelines, the use of albumin dropped by more than 50% from 3178 units in 1996 to 1565 units in 1997. This led to direct cost savings of approximately US$100000.


CONCLUSIONS
The available literature about the risks and benefits of using albumin in clinical practice is not conclusive. The use of albumin should therefore be restricted according to the guidelines.
Natsch
S
S
Department of Clinical Pharmacy, University Hospital Nijmegen, The Netherlands.
van Leeuwen
S J
SJ
de Jong
R
R
Hekster
Y A
YA
D003422:Critical Care / Q000191:economics / Q000592:standards*; D004363:Drug Utilization / Q000191:economics / Q000592:standards*; D006801:Humans; D009426:Netherlands; D017410:Practice Guidelines as Topic; D011786:Quality Control; D012709:Serum Albumin / Q000009:adverse effects / Q000172:deficiency / Q000627:therapeutic use*; D013997:Time Factors
D012709:Serum Albumin